Secondary care notes

• NMUH approvals:
  
  • Restricted for patients allergic to Warfain only.
  • Check MHRA Drug Safety Updates
• RFL approvals:
  
  • Not applicable
• RNOH approvals:
  
  • Not applicable
• UCLH approvals:
• WH approvals:
  
  • Not applicable

See NICE TA for eligibity criteria

Secondary care notes

• NMUH approvals:
  
  • Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
  • See links below
  • Check MHRA Drug Safety Update
  • A referral form must be completed by Authorised Teams/ Haematology team to initiate a DOAC
  • A GP notification form must be completed and sent to the GP for each patient newly started on a DOAC
  • A copy of the above forms (referral form and GP notification form) must be sent to the anticoagulant clinic
• RFL approvals:
  
  • Not applicable
• RNOH approvals:
  
  • Nil
• UCLH approvals:
• WH approvals:
  
  • 2nd Choice DOAC - For Atrial Fibrillation / Stroke prevention.

See NICE TA for eligibity criteria

Secondary care notes

• NMUH approvals:
  
  • Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
  • Restricted for thromboprophylaxis post elective total hip or knee replacement surgery and emergency hip fracture surgery, as per Trust guidelines.
  • See links below
  • Check MHRA Drug Safety Updates
  • A referral form must be completed by Authorised Teams/ Haematology team to initiate a DOAC
  • A GP notification form must be completed and faxed to the GP for each patient newly started on a DOAC
  • A copy of the above forms (referral form and GP notification form) must be sent to the anticoagulant clinic
• RFL approvals:
  
  • Not applicable
• RNOH approvals
  
  • Not applicable
• UCLH approvals:
• WH approvals:
  
  • Restricted for use as thromboprophylaxis after elective hip and knee surgery

See NICE TA for eligibity criteria

Secondary care notes

• NMUH approvals:
  
  • Positive NICE TA - This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
  • A referral form must be completed by Authorised Teams/ Haematology team to initiate a DOAC
  • A GP notification form must be completed and sent to the GP for each patient newly started on a DOAC
  • A copy of the above forms (referral form and GP notification form) must be sent to the anticoagulant clinic
• RFL approvals:
  
  • Not applicable
• RNOH approvals:
  
  • Nil
• UCLH approvals:
• WH approvals:
  
  • Not to be used for initiation of therapy.

Secondary care notes

• NMUH approvals:
  
  • Not applicable
• RFL approvals:
  
  • Should only be used in patients who are allergic to warfarin.
• RNOH approvals
  
  • Not applicable
• UCLH approvals:
• WH approvals:
  
  • Not applicable

Secondary care notes

• NMUH approvals:
  
  • Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
  • For thromboprophylaxis for patients immobilised with lower limb plaster casts. Patient must have had a risk assessment for VTE and must receive the Trust Rivaroxaban Information for Patients leaflet (see links below).
  • Restricted to Haematologists only
  • Check MHRA Drug Safety Updates
  • A referral form must be completed by Authorised Teams/ Haematology team to initiate a DOAC
  • A GP notification form must be completed and sent to the GP for each patient newly started on a DOAC
  • A copy of the above forms (referral form and GP notification form) must be sent to the anticoagulant clinic
  • see links below
• RFL approvals:
  
  • Under haemophilia approval for treatment of DVT only
• RNOH approvals:
  
  • Nil
• UCLH approvals:
• WH approvals:
  
  • 1st Choice - For Atrial Fibrillation / Stroke prevention.

Secondary care notes

• NMUH approvals:
  
  • See links below
  • Check MHRA drug safety update
• RFL approvals:
  
  • See links below
• RNOH approvals
  
  • Nil
• UCLH approvals:
• WH approvals:
  
  • Nil